Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.
All News
A controlled trial has shown that apremilast is effective in patients with early, oligoarticular psoriatic arthritis (PsA).
The British Society for Rheumatology (BSR) has updated its 2015 guidelines for the management of patients with sytemic sclerosis (SSc) based on published evidence, systematic literature review and expert opinion.
A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.
A large EMR derived cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on its prevalence and associated features.
Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week with a focus on fingers and better prescriptive follow through.
Urticarial vasculitis is rare and the causes often go undiagnosed. A Medscape recent overview highlights key features in the diagnosis and management of this rare disorder.
The results of a randomised, open-label, head-to-head trial shows that adalimumab was superior to ciclosporin in preventing uveitis relapses in patients with severe Behçet's disease.
Dr. Jack Cush picks highlight reports from the past week on RheumNow.com, with reports on the challenge of lupus nephritis, perplexing skin issues, you don't know JAK (about Tyk) and the value of a good family history.
Psoriatic arthritis (PsA) is a sequelae to chronic skin psoriasis. Whether cutaneous psoriasis is the pre-clinical phase of what may become PsA is oft debated and has been inadequately researched, largely using claims data or retrospective data sets.
